Anaconda Biomed closes $56m financing for stroke-device clinical development
Omega Funds leads the financing, supporting completion of the ATHENA trial, product development and regulatory work.
Capital from new and returning investors
Anaconda Biomed announced a $56 million financing on September 23, 2026, led by Omega Funds. Spain’s Co-Investment Fund, managed by COFIDES, joined as a new investor. Returning backing included Sabadell Asabys II, Ysios-managed funds and CDTI through SICC Innvierte. CDTI’s subsequent account identifies the participating fund vehicles in more detail.
Funding the next clinical and manufacturing steps
The proceeds support completion of ATHENA, the ongoing randomized, 327-participant pivotal study of the ANA Funnel Catheter, alongside product development and global regulatory work. The company also described direct control of development and manufacturing at its Barcelona-area facility as a foundation for expanding its neurovascular product portfolio.
Use of funds
Complete the ongoing ATHENA pivotal IDE study, continue product development and secure global regulatory approvals for the neurovascular portfolio.